203 related articles for article (PubMed ID: 19200836)
1. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines.
Gross S; Geldmacher A; Sharav T; Losch F; Walden P
Vaccine; 2009 May; 27(25-26):3398-400. PubMed ID: 19200836
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of T-cell inhibition: implications for cancer immunotherapy.
Mittendorf EA; Sharma P
Expert Rev Vaccines; 2010 Jan; 9(1):89-105. PubMed ID: 20021308
[TBL] [Abstract][Full Text] [Related]
3. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
4. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
Huang Y; Shah S; Qiao L
Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
[TBL] [Abstract][Full Text] [Related]
5. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
Durrant LG; Pudney V; Spendlove I; Metheringham RL
Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer.
Gross S; Walden P
Immunol Lett; 2008 Feb; 116(1):7-14. PubMed ID: 18164076
[TBL] [Abstract][Full Text] [Related]
7. Making and circumventing tolerance to cancer.
Kammertoens T; Blankenstein T
Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
[TBL] [Abstract][Full Text] [Related]
8. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
Mocellin S; Nitti D
Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
[TBL] [Abstract][Full Text] [Related]
9. Reversal of tumor-mediated immunosuppression.
Vieweg J; Su Z; Dahm P; Kusmartsev S
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):727s-732s. PubMed ID: 17255301
[TBL] [Abstract][Full Text] [Related]
10. Mimotope vaccines for cancer immunotherapy.
Sharav T; Wiesmüller KH; Walden P
Vaccine; 2007 Apr; 25(16):3032-7. PubMed ID: 17276556
[TBL] [Abstract][Full Text] [Related]
11. Immune suppression in the tumor microenvironment.
Gajewski TF; Meng Y; Harlin H
J Immunother; 2006; 29(3):233-40. PubMed ID: 16699366
[TBL] [Abstract][Full Text] [Related]
12. Immune resistance orchestrated by the tumor microenvironment.
Gajewski TF; Meng Y; Blank C; Brown I; Kacha A; Kline J; Harlin H
Immunol Rev; 2006 Oct; 213():131-45. PubMed ID: 16972901
[TBL] [Abstract][Full Text] [Related]
13. Breaking tolerance in cancer immunotherapy: time to ACT.
Overwijk WW
Curr Opin Immunol; 2005 Apr; 17(2):187-94. PubMed ID: 15766680
[TBL] [Abstract][Full Text] [Related]
14. Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy".
Beyer M; Karbach J; Mallmann MR; Zander T; Eggle D; Classen S; Debey-Pascher S; Famulok M; Jäger E; Schultze JL
Cancer Res; 2009 May; 69(10):4346-54. PubMed ID: 19435912
[TBL] [Abstract][Full Text] [Related]
15. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy.
van der Burg SH; Bijker MS; Welters MJ; Offringa R; Melief CJ
Adv Drug Deliv Rev; 2006 Oct; 58(8):916-30. PubMed ID: 16979788
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial cancer immunotherapy.
Hodi FS; Dranoff G
Adv Immunol; 2006; 90():341-68. PubMed ID: 16730268
[TBL] [Abstract][Full Text] [Related]
17. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
18. Influence of p53 on anti-tumor immunity (review).
Bueter M; Gasser M; Lebedeva T; Benichou G; Waaga-Gasser AM
Int J Oncol; 2006 Feb; 28(2):519-25. PubMed ID: 16391808
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.
Fournier P; Schirrmacher V
Expert Rev Vaccines; 2009 Jan; 8(1):51-66. PubMed ID: 19093773
[TBL] [Abstract][Full Text] [Related]
20. Does our current understanding of immune tolerance, autoimmunity, and immunosuppressive mechanisms facilitate the design of efficient cancer vaccines?
Sioud M
Scand J Immunol; 2009 Dec; 70(6):516-25. PubMed ID: 19906192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
